These differences between CAR-T and control T cells implied that EpCAM CAR-T cells could target and infiltrate the tumor lesions, but the lack of chimeric antigen receptor in control T cells caused deleterious side effects through systematic circulation after intravenous injection. Here, EPCAM is linked to neoplasm.